COHR
Coherent, Inc.
COHR has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
COHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Weak | |
| Healthy |
COHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
COHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $232 | — |
| Cheap | 27x | $130 | -44% |
| Fair | 34x | $165 | -29% |
| Current | 48x | $232 | — |
| Expensive | 184x | $886 | +282% |
Historical ranges are pointers, not guarantees.
COHR's PE is in its fair range at 48x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over COHR in the historical PE scenario, which offers more potential upside but is not a forecast.
COHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
COHR has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
COHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.69 | +142% |
| Q3 2026 | $4.83 | +580% |
| Q2 2026 | $4.12 | +$4.64 |
| Q1 2026 | $2.11 | +$2.34 |
| Q4 2025 | $1.03 | +$1.44 |
| Q3 2025 | $0.71 | +$1.94 |
| Q2 2025 | -$0.52 | +$1.32 |
| Q1 2025 | -$0.23 | +$2.64 |
| Q4 2024 | -$0.41 | +$2.41 |
COHR's earnings per share have climbed steadily: $4.83 over the past year, about seven times what it earned the year before, and higher year over year for 10 quarters in a row.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
COHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.4B | +50% |
| Q2 2026 | $2B | +34% |
| Q1 2026 | $1.8B | +21% |
| Q4 2025 | $1.7B | +17% |
| Q3 2025 | $1.6B | +17% |
| Q2 2025 | $1.5B | +16% |
| Q1 2025 | $1.5B | +24% |
| Q4 2024 | $1.4B | +27% |
COHR has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.4 points |
| Q2 2026 | 14% | +18 points |
| Q1 2026 | 10% | +9.6 points |
| Q4 2025 | 10% | +1 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | -4.2% | -9 points |
| Q1 2025 | 0.7% | -1.2 points |
| Q4 2024 | 8.9% | +6.1 points |
COHR's operating margin was 15% last quarter, up 1.4 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over COHR on profitability, with a higher operating margin.
COHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$868.2M | -$810.2M |
| Q2 2026 | -$486.2M | -$485.2M |
| Q1 2026 | -$383.5M | -850% |
| Q4 2025 | -$95.7M | -217% |
| Q3 2025 | -$58M | -195% |
| Q2 2025 | -$1.1M | -102% |
| Q1 2025 | $51.1M | +111% |
| Q4 2024 | $81.7M | +$106M |
COHR's free cash flow has turned negative after years in the green: −$1.8B over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over COHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
COHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.4% | +6.6M shares |
| 1 year | +5.9% | +11.3M shares |
| 3 years | +34% | +51.7M shares |
| 5 years | +74% | +86.2M shares |
| Available history | +122% | +111M shares |
COHR has 202M diluted shares, up 5.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q2 2020 | — |
| Q1 2020 | $1,000 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over COHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
COHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 4.6x | High |
COHR's net debt is about 1.7 years of its operating earnings (EBITDA), down from 4.1 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over COHR on leverage, with a lower net debt burden relative to earnings.
COHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 16.5 | Oversold |
COHR's weekly RSI is 44 (neutral) and its Stochastic is 16 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
COHR PE vs Technology Sector
| Metric | COHR | Sector median | Relative |
|---|---|---|---|
| PE | 48x | 28x | 72% above |
| PE % | 58 | 35 | 23 pts above |
COHR is trading at 48x earnings, a 72% premium to the Technology sector's median of 28x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over COHR on valuation relative to its sector.
COHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $252.9 | 8.2% below |
| 20 week MA | $284.1 | 18% below |
| 50 week MA | $277.7 | 16% below |
| 100 week MA | $185.9 | 25% above |
| 200 week MA | $120.6 | 92% above |
COHR has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
COHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.5 | $77.8 | +132% |
| 2021 | $77.8 | $68.0 | -13% |
| 2022 | $68.0 | $33.1 | -51% |
| 2023 | $33.1 | $43.5 | +32% |
| 2024 | $43.5 | $97.0 | +123% |
| 2025 | $97.0 | $191.7 | +98% |
| 2026 YTD | $191.7 | $232.1 | +21% |
COHR has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.